$TOVX
Theriva Biologics, Inc.

2017 Q1 Form 10-Q Financial Statement

#000114420417024592 Filed on May 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.090M $3.480M $2.430M
YoY Change -13.99% 37.01% 42.11%
% of Gross Profit
Research & Development $6.059M $6.730M $8.155M
YoY Change -25.7% -24.04% 25.58%
% of Gross Profit
Depreciation & Amortization $57.00K $50.00K $37.00K
YoY Change 54.05% 66.67% 362.5%
% of Gross Profit
Operating Expenses $8.149M $10.20M $8.155M
YoY Change -0.07% -10.45% -0.63%
Operating Profit -$8.149M -$10.58M
YoY Change -22.98% 28.93%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.091M $7.730M -$497.0K
YoY Change -1124.35% 7630.0% -88.03%
Pretax Income -$8.149M -$10.20M -$10.58M
YoY Change -22.98% -10.44% 28.93%
Income Tax
% Of Pretax Income
Net Earnings -$3.058M -$2.472M -$11.08M
YoY Change -72.4% -78.12% -10.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70 -$0.02 -$0.12
Diluted Earnings Per Share -$0.70 -$0.02 -$0.12
COMMON SHARES
Basic Shares Outstanding 3.356M 103.8M shares 90.83M shares
Diluted Shares Outstanding 3.356M 103.8M shares 90.83M shares

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.47M $19.06M $15.10M
YoY Change -10.79% -8.45% 25.31%
Cash & Equivalents $13.47M $19.06M $15.10M
Short-Term Investments
Other Short-Term Assets $175.0K $185.0K $7.116M
YoY Change -97.54% 352.1%
Inventory
Prepaid Expenses $295.0K
Receivables
Other Receivables $0.00
Total Short-Term Assets $16.84M $21.57M $22.22M
YoY Change -24.21% -28.9% 63.11%
LONG-TERM ASSETS
Property, Plant & Equipment $860.0K $905.0K $500.0K
YoY Change 72.0% 83.2% 566.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $20.00K $30.00K
YoY Change -33.33% 100.0% 50.0%
Total Long-Term Assets $880.0K $928.0K $520.0K
YoY Change 69.23% 80.9% 459.14%
TOTAL ASSETS
Total Short-Term Assets $16.84M $21.57M $22.22M
Total Long-Term Assets $880.0K $928.0K $520.0K
Total Assets $17.72M $22.50M $22.74M
YoY Change -22.08% -27.07% 65.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $1.993M $4.600M
YoY Change -17.39% -54.81% 195.06%
Accrued Expenses $2.920M $2.627M $1.820M
YoY Change 60.44% 784.51% -31.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.49M $19.76M $17.53M
YoY Change -5.93% 26.85% 14.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $470.0K $490.0K $240.0K
YoY Change 95.83% 81.48%
Total Long-Term Liabilities $470.0K $490.0K $240.0K
YoY Change 95.83% 81.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.49M $19.76M $17.53M
Total Long-Term Liabilities $470.0K $490.0K $240.0K
Total Liabilities $15.15M $20.25M $16.49M
YoY Change -8.13% 27.82% 7.49%
SHAREHOLDERS EQUITY
Retained Earnings -$172.0M
YoY Change
Common Stock $175.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.570M $3.845M $6.260M
YoY Change
Total Liabilities & Shareholders Equity $17.72M $22.50M $22.74M
YoY Change -22.08% -27.07% 65.79%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q1
OPERATING ACTIVITIES
Net Income -$3.058M -$2.472M -$11.08M
YoY Change -72.4% -78.12% -10.36%
Depreciation, Depletion And Amortization $57.00K $50.00K $37.00K
YoY Change 54.05% 66.67% 362.5%
Cash From Operating Activities -$6.008M -$10.38M -$5.674M
YoY Change 5.89% -5.38% 3.96%
INVESTING ACTIVITIES
Capital Expenditures $11.00K -$370.0K $44.00K
YoY Change -75.0% 825.0% 144.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$11.00K -$370.0K -$44.00K
YoY Change -75.0% 825.0% 144.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $300.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $435.0K 25.26M $0.00
YoY Change 126200.0%
NET CHANGE
Cash From Operating Activities -$6.008M -10.38M -$5.674M
Cash From Investing Activities -$11.00K -370.0K -$44.00K
Cash From Financing Activities $435.0K 25.26M $0.00
Net Change In Cash -$5.584M 14.51M -$5.718M
YoY Change -2.34% -232.03% 4.42%
FREE CASH FLOW
Cash From Operating Activities -$6.008M -$10.38M -$5.674M
Capital Expenditures $11.00K -$370.0K $44.00K
Free Cash Flow -$6.019M -$10.01M -$5.718M
YoY Change 5.26% -8.42% 4.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0141 pure
CY2016Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0139 pure
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000 USD
CY2017Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
166000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2090000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8155000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
8149000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10581000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8149000 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-497000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5091000 USD
CY2016Q1 us-gaap Profit Loss
ProfitLoss
-11078000 USD
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-3058000 USD
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-233000 USD
CY2017Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-212000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10845000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2846000 USD
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
498000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5090000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1052000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2403000 USD
CY2016Q1 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
12000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
184000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
649000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5674000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44000 USD
CY2016Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2016Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-5718000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20818000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15100000 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
592000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1135000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6008000 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-493000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
15000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
37000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57000 USD
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
269000 USD
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
243000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1803000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
435000 USD
CY2017Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-5584000 USD
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
474000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7908899 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
57341642 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
50000000 shares
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
567257 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.60
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
186000 USD
CY2017Q1 syn Accrued Vendor Payments
AccruedVendorPayments
280000 USD
CY2016Q4 syn Accrued Vendor Payments
AccruedVendorPayments
400000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000 USD
CY2017Q1 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2224000 USD
CY2016Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1677000 USD
CY2017Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.885 pure
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 dei Trading Symbol
TradingSymbol
SYN
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
121894034 shares
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
118017693 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117936211 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117254196 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117172714 shares
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
117447260 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90826752 shares
CY2017Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1100000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1700000 USD
CY2017Q1 syn Prepaid Travel And Conference Expenses Current
PrepaidTravelAndConferenceExpensesCurrent
397000 USD
CY2016Q4 syn Prepaid Travel And Conference Expenses Current
PrepaidTravelAndConferenceExpensesCurrent
295000 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1102000 USD
CY2017Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
446000 USD
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 USD
CY2017Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
341000 USD
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
261000 USD
CY2017Q1 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
0 USD
CY2016Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
52000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
787000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
313000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.58
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.35
CY2017Q1 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.17 pure
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5600000 USD
CY2017Q1 us-gaap Share Price
SharePrice
0.63
CY2016Q4 us-gaap Share Price
SharePrice
0.76
CY2016Q4 us-gaap Share Price
SharePrice
1.75
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.0085 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2017Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.014 pure
CY2017Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y6M18D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y9M14D
CY2016Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
57341642 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2017Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.60
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2017Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2846000 USD
CY2016Q1 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2846000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24880000 USD
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117447260 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90826752 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117447260 shares
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90826752 shares
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2017Q1 syn Parepaid Manufacturing Expenses Current
ParepaidManufacturingExpensesCurrent
330000 USD
CY2016Q4 syn Parepaid Manufacturing Expenses Current
ParepaidManufacturingExpensesCurrent
0 USD
CY2017Q1 us-gaap Prepaid Insurance
PrepaidInsurance
240000 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
358000 USD
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
175000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
185000 USD
CY2017Q1 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1812000 USD
CY2016Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
2211000 USD
CY2017Q1 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
38000 USD
CY2016Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
14000 USD

Files In Submission

Name View Source Status
0001144204-17-024592-index-headers.html Edgar Link pending
0001144204-17-024592-index.html Edgar Link pending
0001144204-17-024592.txt Edgar Link pending
0001144204-17-024592-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg16img1_10q.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20170331.xml Edgar Link completed
syn-20170331.xsd Edgar Link pending
syn-20170331_cal.xml Edgar Link unprocessable
syn-20170331_def.xml Edgar Link unprocessable
syn-20170331_lab.xml Edgar Link unprocessable
syn-20170331_pre.xml Edgar Link unprocessable
v464829_10q.htm Edgar Link pending
v464829_ex31-1.htm Edgar Link pending
v464829_ex31-2.htm Edgar Link pending
v464829_ex32-1.htm Edgar Link pending
v464829_ex32-2.htm Edgar Link pending